Puji Xiaodu Powder Veterinary Grade API is supplied under the manufacturer’s model designation PXD-V-API. The material is a multicomponent botanical powder derived from the Puji Xiaodu formula and is released for further manufacturing into tablets, injections, capsules, powders, granules, premixes, and solutions. It is not a finished oral dosage form. The release specification includes identification by HPLC-DAD chromatographic fingerprint against the Chinese Veterinary Pharmacopoeia Puji Xiaodu San monograph, particle size distribution by laser diffraction, loss on drying, bulk and tapped density, elemental impurities, residual solvents, and microbial enumeration. Each batch is accompanied by a certificate of analysis containing multi-marker ratios and a similarity index for the chromatographic envelope; single-marker quantification is not sufficient to establish batch equivalence because the formula contains multiple phenolic, flavonoid, and polysaccharide constituents.

Control of the API grade follows the compliance matrix below. Acceptance values for each parameter are fixed in the supplier’s technical agreement and are not transferable to other botanical powders without revalidation.

Particle size is reported as D10, D50, and D90. Laser diffraction per ISO 13320:2020 is the referee method; the powder is air-jet milled, and the target D90 is normally controlled below 75 µm for injectable-grade dispersions and below 150 µm for dry oral dosage forms. These values are not universal and must be confirmed against the finished-product dissolution or dispersion specification. Loss on drying is measured by USP <731>. A common acceptance limit for this powder is not more than 5.0%. Bulk and tapped density are measured by USP <616>; a Hausner ratio above 1.35 indicates that direct compression may require flow aids. The powder is hygroscopic, and storage should be in sealed aluminum-composite bags at or below 25°C and not more than 60% relative humidity.

Residual solvent analysis is performed by headspace gas chromatography according to USP <467>. Because the botanical extraction may use aqueous ethanol, ethanol is the most commonly observed solvent; Class 1 solvents such as benzene and carbon tetrachloride should be absent at the limit of detection. Elemental impurities are screened by ICP-MS after microwave-assisted acid digestion. Lead, cadmium, arsenic, and mercury are controlled according to the veterinary monograph and USP <232>. The reporting limit for each element should be below the target concentration by a factor of at least 5, but the exact validation is batch-specific.

Microbial enumeration uses membrane filtration because the botanical powder can inhibit growth in direct plating. TAMC and TYMC are reported per USP <61>, and absence of Escherichia coli and Salmonella is evaluated per USP <62>. For injectable-grade material, bacterial endotoxin is measured using a kinetic chromogenic LAL method; the limit is determined by the intended maximum dose and target species.

Why is the veterinary API grade not interchangeable with feed-grade Puji Xiaodu powder?

Feed-grade Puji Xiaodu powder is produced for oral administration in feed or drinking water and is not released under the same pharmaceutical impurity or microbial controls. The veterinary API grade adds control of bacterial endotoxins, residual solvents, elemental impurities, and a defined particle size range. Direct substitution of feed-grade powder in an injectable line can introduce pyrogenic material and filter-blocking particles. The two materials also differ in documentation: the API grade carries a certificate of analysis, stability data, and a chromatographic fingerprint; feed-grade powder typically carries only a botanical identity certificate.

Direct compression of PXD-V-API is limited by the cohesiveness of micronized botanical powder. When the Hausner ratio exceeds 1.35 or the drained angle of repose exceeds 40°, preblending with 0.5% colloidal silicon dioxide and 1% magnesium stearate can be used, but over-lubrication may reduce tablet tensile strength. Dry granulation by roller compaction is preferred for moisture-sensitive formulations; the granulated ribbon should be milled to a granule fraction between 0.8 mm and 1.0 mm before tablet compression. Wet granulation in a high-shear mixer or fluid-bed granulator must keep the product temperature below 60°C to protect thermolabile polyphenolic markers. The endpoint can be monitored by power consumption or torque in high-shear processing; a granule moisture content of 2%–3% before compression is a typical starting point, but the exact value depends on the formulation.

Capsule filling on a tamping-pin or dosator machine requires a plug-forming powder. The milled botanical API often has a low bulk density; densification by slugging or roller compaction improves plug retention. For direct encapsulation without granulation, a glidant and a low moisture content are necessary. The finished capsule should be tested for disintegration per USP <701>. Content uniformity testing requires the final blend to achieve a coefficient of variation of not more than 5% across 10 sampling locations.

For film-coated tablets, the core tablet containing PXD-V-API may have hygroscopic swelling; film coating with a hydroalcoholic or aqueous dispersion should be applied at a pan bed temperature below 50°C to prevent edge chipping. Tablet hardness should be controlled to 60–100 N for conventional round biconvex tools, but actual hardness depends on tablet diameter and shape. Friability testing per USP <1216> must show weight loss not more than 1.0%.

Injectable and solution dosage-form constraints

PXD-V-API is not sterile upon receipt. Parenteral dosage forms must be manufactured by aseptic processing or terminal sterilisation after a validated bioburden reduction step. The botanical matrix may contain high molecular weight polysaccharides that foul sterilising-grade filters; membrane compatibility studies with PVDF and PES membranes should be completed before batch scale-up. A 0.22 µm filter is the standard sterilising grade, but the maximum filter loading per 10 cm² must be determined by pressure-rise testing. Endotoxin limits are aligned with the target species and route; LAL testing per USP <85> is used for release of injectable-grade material.

If terminal sterilisation is considered, the stability-indicating HPLC fingerprint must show no new peaks and marker recovery within 90%–110% of the unsterilised control; otherwise aseptic filtration is required. For injectable solutions, the API should be sieved through a 100-mesh screen before use to remove agglomerates. Aqueous vehicles for injection should be purged with nitrogen if the polyphenolic fraction is oxygen-sensitive; antioxidant systems such as sodium metabisulfite should be evaluated for compatibility, because bisulfite can react with certain flavonoid constituents. Sterile filtration should be performed at constant pressure rather than constant flow to reduce membrane fouling.

When the API is formulated as a premix or drinking-water powder

Premix and drinking-water formulations require a different particle-size and carrier strategy. The API should be premixed with a diluent such as lactose monohydrate or dextrose monohydrate before final blending to improve uniformity. Mixing validation requires sampling at no fewer than 10 points and a coefficient of variation of not more than 5%. Because the powder may disperse rather than dissolve completely in water, hard water containing calcium and magnesium can reduce dispersion stability and cause sedimentation; a pH adjustment or chelating agent may be required if field water hardness is above 200 mg/L as CaCO3.

Premix particle size should be matched to the carrier; if the carrier is granular corncob, the API should be bound to the carrier with 1%–2% of a food-grade binder such as starch paste or povidone K30 to reduce segregation. Granules intended for oral solution should be extruded through a 0.8 mm screen and dried at inlet air temperature not exceeding 60°C. The final premix should be packaged in opaque bags because light exposure can accelerate degradation of yellow-orange chromophores in the botanical matrix. Avoid contact with strong oxidising agents, cationic metal salts, and amine-based additives because these may complex with polyphenolic constituents and reduce assay recovery.

Human-grade botanical APIs cannot be substituted without species-specific validation

Human-grade botanical APIs may not automatically meet veterinary requirements. The impurity, residue, and endotoxin profile may be suitable for human oral solid dosage forms but not for veterinary parenterals or species-specific residue controls. Veterinary registration in many jurisdictions requires stability data generated in the relevant target species and adherence to the Chinese Veterinary Pharmacopoeia or equivalent veterinary compendial monographs. The PXD-V-API model is therefore distinct from human-grade material not by extraction chemistry alone but by the analytical release panel, documentation, and intended-use validation. Published data for this specific botanical API in target species is limited; residue depletion and pharmacokinetic studies must be generated for each finished formulation.

Processing boundaries include pre-drying at relative humidity above 60%, terminal sterilisation only after chromatographic stability confirmation, and avoidance of concurrent use with amine-based additives. The powder is not intended for direct administration without dose calculation from the active marker content. Each finished dosage form must be validated for content uniformity, dissolution, and stability under ICH/VICH conditions.